Godavari Drugs Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Godavari Drugs Ltd is ₹ 124.95 as of 05 May 15:30 . The P/E Ratio of Godavari Drugs Ltd changed from 8.4 on March 2021 to 15 on March 2025 . This represents a CAGR of 12.30% over 5 yearsThe P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 years The Market Cap of Godavari Drugs Ltd changed from ₹ 34.45 crore on March 2021 to ₹ 65.86 crore on March 2025 . This represents a CAGR of 13.84% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 years The revenue of Godavari Drugs Ltd for the Jun '25 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 22.45 crore. This represent the decline of -100% The revenue of Novartis India Ltd for the Jun '25 is ₹ 98.16 crore as compare to the Dec '25 revenue of ₹ 94.65 crore. This represent the growth of 3.71% The ebitda of Godavari Drugs Ltd for the Jun '25 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2.75 crore. This represent the decline of -100% The ebitda of Novartis India Ltd for the Jun '25 is ₹ 37.85 crore as compare to the Dec '25 ebitda of ₹ 31.11 crore. This represent the growth of 21.67% The net profit of Godavari Drugs Ltd changed from ₹ 1.63 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 27.62 crore over 7 quarters. This represents a CAGR of 4.11% The Dividend Payout of Godavari Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India..
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Godavari Drugs Ltd and Novartis India Ltd

Which company has a larger market capitalization, Godavari Drugs Ltd or Novartis India Ltd?

Market cap of Godavari Drugs Ltd is 126 Cr while Market cap of Novartis India Ltd is 2,563 Cr

What are the key factors driving the stock performance of Godavari Drugs Ltd and Novartis India Ltd?

The stock performance of Godavari Drugs Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Godavari Drugs Ltd and Novartis India Ltd?

As of May 5, 2026, the Godavari Drugs Ltd stock price is INR ₹124.95. On the other hand, Novartis India Ltd stock price is INR ₹1038.1.

How do dividend payouts of Godavari Drugs Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Godavari Drugs Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.